C5U
dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Find entries where: C5U
is present as a standalone ligand in 1 entries
Chemical Component Summary | |
---|---|
Name | dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
Identifiers | dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
Formula | C17 H18 N2 O6 |
Molecular Weight | 346.335 |
Type | NON-POLYMER |
Isomeric SMILES | CC1=C(C(C(=C(N1)C)C(=O)OC)c2ccccc2N(=O)=O)C(=O)OC |
InChI | InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 |
InChIKey | HYIMSNHJOBLJNT-UHFFFAOYSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 43 |
Chiral Atom Count | 0 |
Bond Count | 44 |
Aromatic Bond Count | 6 |
Drug Info: DrugBank
DrugBank ID | DB01115 |
---|---|
Name | Nifedipine |
Groups | approved |
Description | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action.[A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383] |
Synonyms |
|
Brand Names |
|
Indication | Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina.[L11383] Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.[L11389,L1245] |
Categories |
|
ATC-Code |
|
CAS number | 21829-25-4 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Voltage-dependent L-type calcium channel subunit alpha-1C | MVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAAL... | unknown | inhibitor |
Voltage-dependent L-type calcium channel subunit alpha-1D | MMMMMMMKKMQHQRQQQADHANEANYARGTRLPLSGEGPTSQPNSSKQTV... | unknown | inhibitor |
Voltage-dependent L-type calcium channel subunit beta-2 | MVQRDMSKSPPTAAAAVAQEIQMELLENVAPAGALGAAAQSYGKGARRKN... | unknown | inhibitor |
Nuclear receptor subfamily 1 group I member 2 | MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATG... | unknown | agonist |
Calmodulin | MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQ... | unknown | inhibitor |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL193 |
PubChem | 4485 |
ChEMBL | CHEMBL193 |
ChEBI | CHEBI:7565 |
CCDC/CSD | BICCIZ05, BICCIZ14, BICCIZ12, ASATOD, JENMUN01, SUZGEA, BICCIZ13, BICCIZ02, BICCIZ06, BICCIZ07, QUPRUP, BICCIZ03, JENMUN, JENMOH, BICCIZ09, BICCIZ, BICCIZ04, BICCIZ15, WEKDUP |